文献速递胸部肿瘤乳腺癌头颈与中枢神经肿瘤

脑转移患者特征、治疗方式与生存的变化:三十年观察期内六千零三十一例患者的数据

Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
PubMed 文献 · Eur J Cancer · 2022-01-05

基于维也纳脑转移登记库1986至2020年间六千零三十一例新诊断脑转移患者,无症状脑转移比例从20.2%升至30.6%,神经外科手术减少而放疗和全身治疗增加,中位总生存从5个月延长至7个月,驱动基因突变影响临床表现与预后。

要点

  • 无症状脑转移比例从1986-1999年的20.2%升至2010-2020年的30.6%(p < 0.001)。
  • 神经外科手术从30.8%降至19.5%,放疗从65.0%升至73.3%,全身治疗从1.0%升至2.0%(p < 0.001)。
  • 中位总生存从5个月延长至7个月(p = 0.001),驱动基因突变影响预后。

核心结论

  • 过去数十年脑转移患者的症状表现和治疗策略呈现变化趋势,原发肿瘤类型和可靶向驱动突变影响临床表现与预后。
  • 未来脑转移特异性试验需考虑现代脑转移队列的构成及可靶向驱动突变患者的不同临床病程。

研究设计与样本

  • 基于维也纳脑转移登记库的观察性研究,纳入1986年至2020年间新诊断脑转移的六千零三十一例不同实体瘤患者。

主要发现

  • 无症状脑转移比例从1986-1999年的20.2%升至2010-2020年的30.6%(p < 0.001)。
  • 癌基因成瘾性非小细胞肺癌和BRAF阳性黑色素瘤的无症状脑转移比例高于野生型肿瘤(p < 0.05)。
  • 神经外科手术从1986-1999年的30.8%降至2010-2020年的19.5%,放疗从65.0%升至73.3%,全身治疗从1.0%升至2.0%(p < 0.001)。
  • 中位总生存从1986-1999年的5个月延长至2010-2020年的7个月(p = 0.001)。
  • 癌基因成瘾性非小细胞肺癌、BRAF阳性黑色素瘤和激素受体阳性乳腺癌患者的生存时间长于其他癌症亚型(p > 0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An accurate classification of patients with brain metastases (BMs) is an important foundation to guide individualised treatment decisions and to formulate BM cohorts for modern clinical trials. METHODS: Six thousand and thirty-one patients with newly diagnosed BM from different solid tumours treated between 1986 and 2020 were identified from the Vienna Brain Metastasis Registry. RESULTS: A rising fraction of patients presented with asymptomatic BM during the observation period (1986-1999: 20.2% vs 2010-2020: 30.6%; p < 0.001). Especially, oncogene-addicted non-small-cell lung cancer (NSCLC) and BRAF (v-Raf murine sarcoma viral oncogene homolog)-positive melanoma had a higher rate of asymptomatic BM presentation compared with wild-type tumours (p < 0.05). Significant changes of initial BM treatment approaches were observed with a decrease of neurosurgical procedures (1986-1999: 30.8% vs 2010-2020: 19.5%) and an increase of radiation treatments (1986-1999: 65.0% vs 2010-2020: 73.3%) and systemic therapies (1986-1999: 1.0% vs 2010-2020: 2.0%; p < 0.001). Median overall survival (OS) was heterogeneous between primary tumour entities but with an overall increase over the decades (median OS 1986-1999: 5 months vs 2010-2020: 7 months; p = 0.001). Survival times were longer in patients with oncogene-addicted NSCLC, BRAF-positive melanoma and hormone receptor-positive breast cancer compared with the other cancer subtypes (p > 0.05). CONCLUSION: Our data highlight shifting trends in the symptomatic presentation and in treatment strategies of patients with BM over the last decades. Entity specific aspects and, in particular, the presence of targetable driver mutation impact the clinical presentation and prognosis. Future BM specific trials need to address the modern composition of BM cohorts and the distinct clinical course of patients with targetable driver mutations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Steindl A, Brunner TJ, Heimbach K, et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer. 2022. PMID: 34998049. doi:10.1016/j.ejca.2021.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。